Alemtuzumab-related eosinophilic central nervous system vasculitis

Mult Scler. 2020 Oct;26(12):1602-1606. doi: 10.1177/1352458519898113. Epub 2020 Feb 21.

Abstract

A 36-year-old woman with relapsing remitting multiple sclerosis (MS) presented with right-sided spasms, focal seizures and neuropsychiatric symptoms 10 months after her first course of alemtuzumab. Magnetic resonance imaging (MRI) brain imaging revealed multiple foci of T2 hyperintensity. Subsequent blood and cerebrospinal fluid (CSF) testing for progressive multifocal leukoencephalopathy (PML), vasculitis and infective causes was negative. A brain biopsy was performed, revealing a prominent perivascular inflammatory infiltrate with multiple immune cells including eosinophils, suggesting eosinophilic vasculitis. The patient was treated successfully with cyclophosphamide. The potential sequelae of alemtuzumab treatment are discussed; this treatable complication should be considered when tests for JC virus are negative.

Keywords: Multiple sclerosis; alemtuzumab; autoimmune; eosinophilic; vasculitis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alemtuzumab / adverse effects
  • Female
  • Humans
  • JC Virus*
  • Leukoencephalopathy, Progressive Multifocal*
  • Magnetic Resonance Imaging
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy
  • Vasculitis, Central Nervous System* / chemically induced
  • Vasculitis, Central Nervous System* / diagnostic imaging
  • Vasculitis, Central Nervous System* / drug therapy

Substances

  • Alemtuzumab